ArticleInfection and drug resistance2022
Prevalence and Molecular Characterization of Extended Spectrum β-Lactamase and Carbapenemase-Producing
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Prevalence of carbapenemase-producing Enterobacteriaceae from human clinical samples in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Molecular detection of extended-spectrum β-Lactamase genes in multi-drug-resistant bacteria isolated from drinking water supply and surface water systems in Addis Ababa, Ethiopia.BMC microbiology · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Klebsiella pneumoniae in humans, animals and the environment in Northwest Amhara, Ethiopia.Scientific reports · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Escherichia coli from patients, cattle, and environmental sources in northwest Amhara, Ethiopia: a one health approach.BMC microbiology · 2026Article
- Molecular characterization of virulence and antibiotic resistance genes in Klebsiella pneumoniae isolated from sputum samples at a tertiary hospital in Ethiopia.Scientific reports · 2026Article
- High Prevalence of ESBL-Producing Enterobacteriaceae and Antimicrobial Resistance Patterns in a Tertiary Care Hospital in Mogadishu, Somalia: A Retrospective Cross-Sectional Study.Infection and drug resistance · 2026Article
- Resistance gene profiling of beta-lactamase and carbapenemase in gram-negative blood isolates: A tertiary care hospital.PloS one · 2026Article
- Article
- Prevalence, multidrug resistance patterns, and carbapenemase-encoding genes of carbapenemase-producingSAGE open medicine · 2026Review
- Gut colonization, acquisition, and persistence of β-lactamase-producing Enterobacterales among hospitalized patients in Addis Ababa, Ethiopia.BMC infectious diseases · 2025Article
- Detection of ESBL-producingJournal of clinical microbiology · 2025Article
- Whole-Genome Sequencing of Extended-Spectrum β-Lactamase-ProducingPathogens (Basel, Switzerland) · 2025Article
- Investigation of methicillin, beta lactam, carbapenem, and multidrug resistant bacteria from blood cultures of septicemia suspected patients in Northwest Ethiopia.Scientific reports · 2025Article
- Genetic profiling of extended-spectrum β-Lactamase and carbapenemase-producing Escherichia coli O157:H7 from clinical samples among diarrheal patients in Shashemene, Ethiopia.BMC infectious diseases · 2025Article
- Article
- Global burden and trends ofFrontiers in public health · 2025Article
- Molecular characterization of carbapenem-resistance in Gram-negative isolates obtained from clinical samples at Jimma Medical Center, Ethiopia.Frontiers in microbiology · 2024Article
- Emergence of an Extensive Drug ResistantInfection and drug resistance · 2024Article
- Drug resistance and extended-spectrum β-lactamase (ESBLs) - producing Enterobacteriaceae, Acinetobacter and Pseudomonas species from the views of one-health approach in Ethiopia: a systematic review and meta-analysis.One health outlook · 2023Review
- Antimicrobial Resistance Patterns and Risk Factors Associated with ESBL-Producing and MDRMicroorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Production of Extended spectrum beta-lactamase (ESBL) and Carbapenemase is the most common strategy for drug resistance in clinical isolates of Methods: A cross-sectional study was performed from September 2018 to January 2019 in Ethiopia. A total of 2397 BSI suspected patients were enrolled and blood culture was performed using a BacT/Alert instrument in combination with conventional methods for identification. After antimicrobial susceptibility test, phenotypic confirmation of ESBLs was done by combined disc-diffusion. Meanwhile carbapenemase production was done by modified carbapenem inactivation method. Multiplex PCR was conducted to detect the presence of Results: A total of 104 (4.3%) Conclusion: In our study, the rate of ESBL production among BSI-causing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.